{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:52:27Z","timestamp":1791420747551,"version":"4.3.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":140,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China","award":["81960477"],"award-info":[{"award-number":["81960477"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","award":["2023GXNSFDA026041"],"award-info":[{"award-number":["2023GXNSFDA026041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02306-8","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T19:05:19Z","timestamp":1779390319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tamoxifen-pretreated MSC exosomes promote endocrine resistance in ER-positive breast cancer cells through the miR-137\/Serpina3 axis: a mechanistic study"],"prefix":"10.1186","volume":"28","author":[{"given":"Xiaolan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqian","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2306_CR1","doi-asserted-by":"publisher","first-page":"1298423","DOI":"10.3389\/fendo.2024.1298423","volume":"15","author":"MK McGrath","year":"2024","unstructured":"McGrath MK, Abolhassani A, Guy L, Elshazly AM, Barrett JT, Mivechi NF, Gewirtz DA, Schoenlein PV. Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer. Front Endocrinol. 2024;15:1298423. https:\/\/doi.org\/10.3389\/fendo.2024.1298423.","journal-title":"Front Endocrinol"},{"key":"2306_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323.","journal-title":"JAMA"},{"key":"2306_CR3","doi-asserted-by":"publisher","first-page":"102952","DOI":"10.1016\/j.redox.2023.102952","volume":"68","author":"Z Xu","year":"2023","unstructured":"Xu Z, Wang X, Sun W, Xu F, Kou H, Hu W, Zhang Y, Jiang Q, Tang J, Xu Y. RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer. Redox Biol. 2023;68:102952. https:\/\/doi.org\/10.1016\/j.redox.2023.102952.","journal-title":"Redox Biol"},{"key":"2306_CR4","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.7150\/thno.72599","volume":"12","author":"ML Jin","year":"2022","unstructured":"Jin ML, Yang L, Jeong KW. SETD1A-SOX2 axis is involved in tamoxifen resistance in estrogen receptor \u03b1-positive breast cancer cells. Theranostics. 2022;12:5761\u201375. https:\/\/doi.org\/10.7150\/thno.72599.","journal-title":"Theranostics"},{"key":"2306_CR5","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1038\/s41467-020-19349-w","volume":"11","author":"Q Shi","year":"2020","unstructured":"Shi Q, Li Y, Li S, Jin L, Lai H, Wu Y, Cai Z, Zhu M, Li Q, Li Y, Wang J, Liu Y, Wu Z, Song E, Liu Q. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. Nat Commun. 2020;11:5513. https:\/\/doi.org\/10.1038\/s41467-020-19349-w.","journal-title":"Nat Commun"},{"key":"2306_CR6","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1038\/onc.2010.333","volume":"29","author":"H Aguilar","year":"2010","unstructured":"Aguilar H, Sol\u00e9 X, Bonifaci N, Serra-Musach J, Islam A, L\u00f3pez-Bigas N, M\u00e9ndez-Pertuz M, Beijersbergen RL, L\u00e1zaro C, Urruticoechea A, Pujana MA. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene. 2010;29:6071\u201383. https:\/\/doi.org\/10.1038\/onc.2010.333.","journal-title":"Oncogene"},{"key":"2306_CR7","doi-asserted-by":"publisher","first-page":"121986","DOI":"10.1016\/j.biomaterials.2022.121986","volume":"294","author":"W Jiang","year":"2023","unstructured":"Jiang W, Zhong S, Chen Z, Qian J, Huang X, Zhang H, Wen L, Zhang Y, Yao G. 2D-CuPd nanozyme overcome tamoxifen resistance in breast cancer by regulating the PI3K\/AKT\/mTOR pathway. Biomaterials. 2023;294:121986. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121986.","journal-title":"Biomaterials"},{"key":"2306_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12943-017-0727-3","volume":"16","author":"W-X Peng","year":"2017","unstructured":"Peng W-X, Huang J-G, Yang L, Gong A-H, Mo Y-Y. Linc-RoR promotes MAPK\/ERK signaling and confers estrogen-independent growth of breast cancer. Mol Cancer. 2017;16:161. https:\/\/doi.org\/10.1186\/s12943-017-0727-3.","journal-title":"Mol Cancer"},{"key":"2306_CR9","doi-asserted-by":"publisher","first-page":"7136","DOI":"10.3390\/ijms24087136","volume":"24","author":"K Wang","year":"2023","unstructured":"Wang K, Li Q, Fan Y, Fang P, Zhou H, Huang J. OBHS drives abnormal glycometabolis reprogramming via GLUT1 in breast cancer. Int J Mol Sci. 2023;24:7136. https:\/\/doi.org\/10.3390\/ijms24087136.","journal-title":"Int J Mol Sci"},{"key":"2306_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.canlet.2021.07.015","volume":"518","author":"BJ Petri","year":"2021","unstructured":"Petri BJ, Piell KM, South Whitt GC, Wilt AE, Poulton CC, Lehman NL, Clem BF, Nystoriak MA, Wysoczynski M, Klinge CM. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells. Cancer Lett. 2021;518:152\u201368. https:\/\/doi.org\/10.1016\/j.canlet.2021.07.015.","journal-title":"Cancer Lett"},{"key":"2306_CR11","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s40265-020-01394-w","volume":"80","author":"SE Nunnery","year":"2020","unstructured":"Nunnery SE, Mayer IA. Targeting the PI3K\/AKT\/mTOR pathway in hormone-positive breast cancer. Drugs. 2020;80:1685\u201397. https:\/\/doi.org\/10.1007\/s40265-020-01394-w.","journal-title":"Drugs"},{"key":"2306_CR12","doi-asserted-by":"publisher","first-page":"13311","DOI":"10.3390\/ijms222413311","volume":"22","author":"K Pansy","year":"2021","unstructured":"Pansy K, Uhl B, Krstic J, Szmyra M, Fechter K, Santiso A, Th\u00fcminger L, Greinix H, Kargl J, Prochazka K, Feichtinger J, Deutsch AJ. Immune regulatory processes of the tumor microenvironment under malignant conditions. Int J Mol Sci. 2021;22:13311. https:\/\/doi.org\/10.3390\/ijms222413311.","journal-title":"Int J Mol Sci"},{"key":"2306_CR13","doi-asserted-by":"publisher","unstructured":"Yamauchi M, Gibbons DL, Zong C, Fradette JJ, Bota-Rabassedas N, Kurie JM. Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. Matrix Biol J Int Soc Matrix Biol. 2020. https:\/\/doi.org\/10.1016\/j.matbio.2020.05.001.","DOI":"10.1016\/j.matbio.2020.05.001"},{"key":"2306_CR14","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11:933\u201359. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1808.","journal-title":"Cancer Discov"},{"key":"2306_CR15","doi-asserted-by":"publisher","first-page":"e2106265","DOI":"10.1002\/adma.202106265","volume":"34","author":"F Xu","year":"2022","unstructured":"Xu F, Fei Z, Dai H, Xu J, Fan Q, Shen S, Zhang Y, Ma Q, Chu J, Peng F, Zhou F, Liu Z, Wang C. Mesenchymal stem cell-derived extracellular vesicles with high PD-L1 expression for autoimmune diseases treatment. Adv Mater Deerfield Beach Fla. 2022;34:e2106265. https:\/\/doi.org\/10.1002\/adma.202106265.","journal-title":"Adv Mater Deerfield Beach Fla"},{"key":"2306_CR16","doi-asserted-by":"publisher","first-page":"104843","DOI":"10.1016\/j.phrs.2020.104843","volume":"157","author":"T Li","year":"2020","unstructured":"Li T, Zhou X, Wang J, Liu Z, Han S, Wan L, Sun X, Chen H. Adipose-derived mesenchymal stem cells and extracellular vesicles confer antitumor activity in preclinical treatment of breast cancer. Pharmacol Res. 2020;157:104843. https:\/\/doi.org\/10.1016\/j.phrs.2020.104843.","journal-title":"Pharmacol Res"},{"key":"2306_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.stem.2009.02.001","volume":"4","author":"JM Karp","year":"2009","unstructured":"Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4:206\u201316. https:\/\/doi.org\/10.1016\/j.stem.2009.02.001.","journal-title":"Cell Stem Cell"},{"key":"2306_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cellimm.2017.07.011","volume":"326","author":"HS Eltoukhy","year":"2018","unstructured":"Eltoukhy HS, Sinha G, Moore CA, Sandiford OA, Rameshwar P. Immune modulation by a cellular network of mesenchymal stem cells and breast cancer cell subsets: Implication for cancer therapy. Cell Immunol. 2018;326:33\u201341. https:\/\/doi.org\/10.1016\/j.cellimm.2017.07.011.","journal-title":"Cell Immunol"},{"key":"2306_CR19","doi-asserted-by":"publisher","first-page":"121848","DOI":"10.1016\/j.biomaterials.2022.121848","volume":"290","author":"F An","year":"2022","unstructured":"An F, Hou Z, Wang X, Wang Z, Jing C, Sui R, Wu Y, Ma Y, Chang C, Liu S, Li M, Sun L, Gao Z, Zhang W, Lang Z, Zhao J, Qu Y, Xu L, Luo Y, Yan J, Wang Y, Xu J, Liu Q. A microfluidic demonstration of cluster-sprout-infiltrating mode for hypoxic mesenchymal stem cell guided cancer cell migration. Biomaterials. 2022;290:121848. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121848.","journal-title":"Biomaterials"},{"key":"2306_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-009-0458-2","volume":"121","author":"LV Rhodes","year":"2010","unstructured":"Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat. 2010;121:293\u2013300. https:\/\/doi.org\/10.1007\/s10549-009-0458-2.","journal-title":"Breast Cancer Res Treat"},{"key":"2306_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jconrel.2022.05.027","volume":"347","author":"I Kimiz-Gebologlu","year":"2022","unstructured":"Kimiz-Gebologlu I, Oncel SS. Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. J Control Release Off J Control Release Soc. 2022;347:533\u201343. https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.027.","journal-title":"J Control Release Off J Control Release Soc"},{"key":"2306_CR22","unstructured":"Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/36100944\/ Accessed 19 April 2025."},{"key":"2306_CR23","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1158\/0008-5472.CAN-16-1092","volume":"76","author":"SA Bliss","year":"2016","unstructured":"Bliss SA, Sinha G, Sandiford OA, Williams LM, Engelberth DJ, Guiro K, Isenalumhe LL, Greco SJ, Ayer S, Bryan M, Kumar R, Ponzio NM, Rameshwar P. Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res. 2016;76:5832\u201344. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1092.","journal-title":"Cancer Res"},{"key":"2306_CR24","doi-asserted-by":"publisher","first-page":"8733","DOI":"10.2147\/CMAR.S270200","volume":"12","author":"Z Jia","year":"2020","unstructured":"Jia Z, Zhu H, Sun H, Hua Y, Zhang G, Jiang J, Wang X. Adipose mesenchymal stem cell-derived exosomal microRNA-1236 reduces resistance of breast cancer cells to cisplatin by suppressing SLC9A1 and the Wnt\/\u03b2-Catenin signaling. Cancer Manag Res. 2020;12:8733\u201344. https:\/\/doi.org\/10.2147\/CMAR.S270200.","journal-title":"Cancer Manag Res"},{"key":"2306_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.omto.2020.10.008","volume":"19","author":"T Luo","year":"2020","unstructured":"Luo T, Liu Q, Tan A, Duan L, Jia Y, Nong L, Tang J, Zhou W, Xie W, Lu Y, Yu Q, Liu Y. Mesenchymal stem cell-secreted exosome promotes chemoresistance in breast cancer via enhancing miR-21-5p-mediated S100A6 expression. Mol Ther Oncolytics. 2020;19:283\u201393. https:\/\/doi.org\/10.1016\/j.omto.2020.10.008.","journal-title":"Mol Ther Oncolytics"},{"key":"2306_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/biomedicines11010156","volume":"11","author":"M de Mezer","year":"2023","unstructured":"de Mezer M, Rogali\u0144ski J, Przewo\u017any S, Chojnicki M, Niepolski L, Sobieska M, Przysta\u0144ska A. SERPINA3: stimulator or inhibitor of pathological changes. Biomedicines. 2023;11:156. https:\/\/doi.org\/10.3390\/biomedicines11010156.","journal-title":"Biomedicines"},{"key":"2306_CR27","doi-asserted-by":"publisher","first-page":"188760","DOI":"10.1016\/j.bbcan.2022.188760","volume":"1877","author":"A Soman","year":"2022","unstructured":"Soman A, Asha S, Nair. Unfolding the cascade of SERPINA3: inflammation to cancer. Biochim Biophys Acta Rev Cancer. 2022;1877:188760. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188760.","journal-title":"Acta Rev Cancer"},{"issue":"5","key":"2306_CR28","doi-asserted-by":"publisher","first-page":"188760","DOI":"10.1016\/j.bbcan.2022.188760","volume":"1877","author":"A Soman","year":"2022","unstructured":"Soman A, Asha Nair S. Unfolding the cascade of SERPINA3: inflammation to cancer. Biochimica et Biophysica acta Rev Cancer. 2022;1877(5):188760. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188760.","journal-title":"Reviews Cancer"},{"issue":"4","key":"2306_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s12282-021-01221-4","volume":"28","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Tian J, Qu C, et al. Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells. Breast Cancer. 2021;28(4):859\u201373. https:\/\/doi.org\/10.1007\/s12282-021-01221-4.","journal-title":"Breast Cancer"},{"key":"2306_CR30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s12282-021-01221-4","volume":"28","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Tian J, Qu C, Peng Y, Lei J, Li K, Zong B, Sun L, Liu S. Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells. Breast Cancer Tokyo Jpn. 2021;28:859\u201373. https:\/\/doi.org\/10.1007\/s12282-021-01221-4.","journal-title":"Breast Cancer Tokyo Jpn"},{"key":"2306_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s42003-023-05065-w","volume":"6","author":"J Zhou","year":"2023","unstructured":"Zhou J, Zhu M, Wang Q, Deng Y, Liu N, Liu Y, Liu Q. SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition. Commun Biol. 2023;6:695. https:\/\/doi.org\/10.1038\/s42003-023-05065-w.","journal-title":"Commun Biol"},{"key":"2306_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12935-020-01736-4","volume":"21","author":"Y Chen","year":"2021","unstructured":"Chen Y, Geng Y, Huang J, Xi D, Xu G, Gu W, Shao Y. CircNEIL3 promotes cervical cancer cell proliferation by adsorbing miR-137 and upregulating KLF12. Cancer Cell Int. 2021;21:34. https:\/\/doi.org\/10.1186\/s12935-020-01736-4.","journal-title":"Cancer Cell Int"},{"key":"2306_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1615\/CritRevEukaryotGeneExpr.2022041013","volume":"32","author":"X-Q Weng","year":"2022","unstructured":"Weng X-Q, Wang W. miR-137 modulates human gastric cancer cell proliferation, apoptosis, and migration by targeting EZH2. Crit Rev Eukaryot Gene Expr. 2022;32:31\u201340. https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2022041013.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"2306_CR34","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.21037\/tcr-22-2177","volume":"11","author":"Y Luo","year":"2022","unstructured":"Luo Y, Hu S, Wang F, Yang J, Gong D, Xu W, Xu X, Min L. miR-137 represses migration and cell motility by targeting COX-2 in non-small cell lung cancer. Transl Cancer Res. 2022;11:3803\u201313. https:\/\/doi.org\/10.21037\/tcr-22-2177.","journal-title":"Transl Cancer Res"},{"key":"2306_CR35","unstructured":"miR-137-LAPTM4B regulates cytoskeleton organization and cancer metastasis via the RhoA-LIMK-Cofilin pathway in osteosarcoma - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/37147294\/ Accessed 19 April 2025."},{"key":"2306_CR36","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/s41418-017-0053-8","volume":"25","author":"M Luo","year":"2018","unstructured":"Luo M, Wu L, Zhang K, Wang H, Zhang T, Gutierrez L, O\u2019Connell D, Zhang P, Li Y, Gao T, Ren W, Yang Y. miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. Cell Death Differ. 2018;25:1457\u201372. https:\/\/doi.org\/10.1038\/s41418-017-0053-8.","journal-title":"Cell Death Differ"},{"key":"2306_CR37","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1159\/000491526","volume":"47","author":"F Chen","year":"2018","unstructured":"Chen F, Luo N, Hu Y, Li X, Zhang K. MiR-137 suppresses triple-negative breast cancer stemness and tumorigenesis by perturbing BCL11A-DNMT1 interaction. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2018;47:2147\u201358. https:\/\/doi.org\/10.1159\/000491526.","journal-title":"Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"key":"2306_CR38","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/s41419-019-2164-2","volume":"10","author":"F Du","year":"2019","unstructured":"Du F, Yu L, Wu Y, Wang S, Yao J, Zheng X, Xie S, Zhang S, Lu X, Liu Y, Chen W. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4. Cell Death Dis. 2019;10:922. https:\/\/doi.org\/10.1038\/s41419-019-2164-2.","journal-title":"Cell Death Dis"},{"key":"2306_CR39","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3390\/cancers11111704","volume":"11","author":"J Lokau","year":"2019","unstructured":"Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma. Cancers. 2019;11:1704. https:\/\/doi.org\/10.3390\/cancers11111704.","journal-title":"Cancers"},{"key":"2306_CR40","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1074\/jbc.273.7.4112","volume":"273","author":"T Kordula","year":"1998","unstructured":"Kordula T, Rydel RE, Brigham EF, Horn F, Heinrich PC, Travis J. Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha1-antichymotrypsin expression in human cortical astrocytes. J Biol Chem. 1998;273:4112\u20138. https:\/\/doi.org\/10.1074\/jbc.273.7.4112.","journal-title":"J Biol Chem"},{"key":"2306_CR41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3892\/ijo.2023.5544","volume":"63","author":"Y Jin","year":"2023","unstructured":"Jin Y, Zhang Y, Huang A, Chen Y, Wang J, Liu N, Wang X, Gong Y, Wang W, Pan J. Overexpression of SERPINA3 suppresses tumor progression by modulating SPOP\/NF\u2013\u03baB in lung cancer. Int J Oncol. 2023;63:96. https:\/\/doi.org\/10.3892\/ijo.2023.5544.","journal-title":"Int J Oncol"},{"key":"2306_CR42","unstructured":"Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/7544533\/ Accessed 20 April 2025."},{"key":"2306_CR43","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1097\/00001756-199511270-00004","volume":"6","author":"U Machein","year":"1995","unstructured":"Machein U, Lieb K, H\u00fcll M, Fiebich BL. IL-1 beta and TNF alpha, but not IL-6, induce alpha 1-antichymotrypsin expression in the human astrocytoma cell line U373 MG. NeuroReport. 1995;6:2283\u20136. https:\/\/doi.org\/10.1097\/00001756-199511270-00004.","journal-title":"NeuroReport"},{"key":"2306_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13058-018-0968-0","volume":"20","author":"V Allouchery","year":"2018","unstructured":"Allouchery V, Beaussire L, Perdrix A, Sefrioui D, Augusto L, Guillemet C, Sarafan-Vasseur N, Di Fiore F, Clatot F. Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients. Breast Cancer Res BCR. 2018;20:40. https:\/\/doi.org\/10.1186\/s13058-018-0968-0.","journal-title":"Breast Cancer Res BCR"},{"key":"2306_CR45","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00109-021-02136-5","volume":"99","author":"O Saatci","year":"2021","unstructured":"Saatci O, Huynh-Dam K-T, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med Berl Ger. 2021;99:1691\u2013710. https:\/\/doi.org\/10.1007\/s00109-021-02136-5.","journal-title":"J Mol Med Berl Ger"},{"key":"2306_CR46","doi-asserted-by":"publisher","unstructured":"Yamamura J, et al. mRNA expression level of estrogen-inducible gene, antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers. Cancer Sci. 2004;95(11):887\u201392. https:\/\/doi.org\/10.1111\/J.1349-7006.2004.TB02198.X.","DOI":"10.1111\/J.1349-7006.2004.TB02198.X"},{"issue":"6","key":"2306_CR47","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1159\/000475648","volume":"41","author":"H Zhu","year":"2017","unstructured":"Zhu H, et al. Alpha1-ACT functions as a tumour suppressor in hepatocellular carcinoma by inhibiting the PI3K\/AKT\/mTOR signalling pathway via activation of PTEN. Cell Physiol Biochem. 2017;41(6):2289\u2013306. https:\/\/doi.org\/10.1159\/000475648.","journal-title":"Cell Physiol Biochem"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02306-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02306-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02306-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:24:38Z","timestamp":1791419078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02306-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2306"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02306-8","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki principles. It was approved by the Ethics Committee of Guangxi Medical University Cancer Hospital (Date March 5, 2024\/No. KY2024171). All methods were performed in accordance with the relevant guidelines and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and agreed to the published version of the manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"171"}}